Daily supplementation of 3.5g RAR-CLA will slow down cognitive decline as compared to placebo
ID
Bron
Verkorte titel
Aandoening
cognitive impairment
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Episodic memory as measured with the RAVLT
Achtergrond van het onderzoek
Objective: The primary objective is to investigate the effect of 12 weeks of supplementation with 3.5g/day of rumenic acid on cognitive functioning in older men and women at risk of cognitive impairment. Secondary objectives include the assessment of the effect of rumenic acid supplementation on mental well-being, handgrip strength, hand joint discomfort, and plasma fatty acid levels.
Study design: Randomized, parallel, double-blind, placebo-controlled trial.
Study population: Elderly (≥ 65 years, n=52) at risk of cognitive impairment.
Intervention: Subjects will receive a daily dose of 3.5g rumenic acid divided over six capsules (intervention) or six placebo capsules (control).
Main study parameters/endpoints: The primary study parameter is episodic memory as measured with the RAVLT. Secondary parameters entail cognitive functioning (episodic and working memory, attention, executive functioning, and psychomotor speed) as measured with a battery of cognitive tests, the evaluation of rumenic acid supplementation on anxiety, depressive symptoms, quality of life (measured with questionnaires), and plasma fatty acid status (measured in blood).
Doel van het onderzoek
Daily supplementation of 3.5g RAR-CLA will slow down cognitive decline as compared to placebo
Onderzoeksopzet
0 weeks and 12 weeks
Onderzoeksproduct en/of interventie
Subjects will receive a daily dose of 3.5g rumenic acid divided over six capsules (intervention) or six placebo capsules (control).
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• Aged ≥65 years
• At risk of cognitive impairment/ memory complaints
• Able to understand and perform the study procedures
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• Body Mass Index (BMI) >35 kg/m2
• Current use of medication belonging to the “sartans” or “glitazones”
• Current use of >500 mg/day of acetylsalicylic acid
• Current use of medication that affects inflammation (anti-inflammatory medication)
• Fish consumption of more than 1 serving per week
• Current or recent (<1 month) use of fish oil supplements
• Current or recent (<1 month) use of anti-inflammatory dietary supplements such as quercetin, curcumin, resveratrol, and/or other flavonoids
• Diabetes mellitus
• Having a disease which interferes with the effect of the RAR-CLA supplement and/or with the outcome measure (cognitive functioning) as judged by medical doctor
• Swallowing problems
• Current participation in other scientific research with the exception of EetMeetWeet!
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7598 |
| Ander register | METC-WU : 18/27 |